GlobeNewswire

Atico Reports Consolidated Financial Results for 2017

Dela

(All amounts expressed in US dollars, unless otherwise stated)

VANCOUVER, British Columbia, April 23, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSX-V:ATY) (OTC:ATCMF) today announced its financial results for the year ended December 31, 2017, posting income from mining operations of $15.32 million and a net income of $4.04 million. Production for the year at Atico's El Roble mine totaled 20.6 million pounds ("lbs") of copper and 10,923 ounces ("oz") of gold in concentrates at a cash cost(1) of $1.45 per payable pound of copper produced(2).            

Fernando E. Ganoza, CEO and Director, commented, "We are pleased to report our strongest year to date both operationally and financially, as the Company concluded 2017 exceeding nearly all set objectives for the year. Operationally, we delivered above our higher end guidance while further increasing operational standards at El Roble. Financially, we have delivered a record year in most metrics while significantly strengthening our balance sheet. These accomplishments allowed us to allocate additional funds to drill test three of the fifteen targets on the 6,600-hectare prospective land package the Company controls. Mr. Ganoza continued, "In 2018, we will focus on organic growth at El Roble property by following up on positive exploration results from the previous year while also testing at least two new regional drill targets. In parallel, the search for a second asset remains to be a high priority as we continue to strive towards our goal of becoming a leading mid-tear producer." 

2017 Consolidated Financial Highlights

  • Net income for the year amounted to $4.04 million, compared with $0.32 million for the previous year. Net income for the year was positively affected by an increase in revenue (increase in realized copper price of 26.2%), partially offset by increases in direct mining and processing costs, and selling, general and administrative expenses.
     
  • Sales for the year increased 49% to $57.00 million when compared with 2016. The increase was due to additional concentrate shipped and provisionally invoiced with a higher realized copper price when compared to 2016. Copper ("Cu") accounted for 97.6% and gold ("Au") 2.4% of total amount provisionally invoiced during the year. The average realized price per metal on provisional invoicing was $2.79 (2016 - $2.21) per pound of copper and $1,265.21 (2016 - $1,256.11) per ounce of gold. 
     
  • Working capital was $4.6 million (2016 - $1.7 million), while the Company repaid principal of $3.1 million (2016 - $2.0 million) on its long-term loans payable with $2.7 million (2016 - $5.6 million) outstanding at the reporting date.
     
  • Cash costs(1) were $118.94 per tonne of processed ore and $1.44 per pound of payable copper produced(2), increases of 20% and 32% over last year, respectively.
     
  • Income from operations was $7.58 million (2016 - $1.56 million) while cash flow from operations, before changes in working capital was $18.18 million (2016 - $11.44 million). Cash used for capital expenditures amounted to $10.18 million (2016 - $8.50 million).
     
  • At the year-end, 3,797 (2016 - 7,366) wet metric tonnes of non-invoiced concentrate remained at the Company's warehouses.
     
  • All-in sustaining cash cost per payable pound of copper produced(1)(2) for the year was $2.05 (2016 - $1.63).

2017 Consolidated Operating Highlights        

  • Ore processed increased 6% year-on-year;
     
  • Copper head grade increased 4% year-on-year;
     
  • Gold head grade decreased 3% year-on-year; 
     
  • Concentrate production increased 3% year-on-year;
     
  • Copper metal production increased 10% year-on-year; and
     
  • Gold metal production decreased 2% year-on-year.

Fourth Quarter Operating and Financial Highlights

  • The Company produced 11,224 dry metric tonnes of concentrate during the quarter with a metal content of 5.3 million pounds of copper, 2,972 ounces of gold and 9,586 oz of silver. 
     
  • Sales of $13.75 million were generated during the quarter, where copper accounted for 98.9% and gold for 1.1% of the total. The average realized price per metal on provisional invoicing was $3.04 per pound of copper and $1,289.88 per ounce of gold. 
     
  • Cash costs(1) for the quarter were $133.24 per tonne of processed ore and $1.67 per pound of payable copper produced(2)
     
  • Cash flow from operations, before changes in working capital, for the quarter was $3.44 million.

2017 Consolidated Operations Review

In 2017, the Company produced 20.6 million lbs of copper, 10,923 oz of gold, and 40,283 oz of silver. When compared to 2016, production increased by 10% for copper and decreased by 2% for gold. The increase in copper produced is mainly explained by 6% more processed material and a 4% increase in the copper head grade. In the case of gold, the increase in processed material was partially offset by a 3% decrease in the gold head grade and a 4% decrease in the metal recovery.

Cash costs(1)(2) were $118.94 per tonne of processed ore and $1.44 per pound of payable copper produced, which was an increase of 20% and 32% over 2016, respectively (refer to non-GAAP Financial Measures). All-in sustaining cash cost per payable pound of copper produced(1)(2) was $2.05.

For fiscal 2017, treatment charges had a variable surcharge component dependent on the copper price. The higher average copper price during fiscal 2017 alone had a negative effect of 12.1% on the cash cost per payable pound of copper produced over 2016. The Company does not anticipate a similar treatment surcharge for fiscal 2018.

Fourth Quarter Operations Review
            
During the quarter, the Company produced 5.3 million lbs of copper, 2,972 oz of gold, and 9,586 oz of silver. When compared to Q4-2016, production increased 4% for copper and 5% for gold. The increases in copper and gold produced are mainly explained by a 2% increase in processed material and 2% and 3% increases in the copper and gold head grades, respectively.

Cash costs(1) for the period were $133.24 per tonne of processed ore, and $1.67 per pound of payable copper produced(2), increases of 40% and 27% over the same period last year, respectively. The increase in the cash cost per pound of payable copper net of by products is mainly explained by the increase in the cost per processed tonne and treatment surcharge, partially offset by a higher gold credit. All-in sustaining cash cost per payable pound of copper produced(1)(2) was $2.28. The treatment surcharge during the quarter had a negative effect of 21.6% on the cash cost per payable pound of copper produced over Q4-2016.

Consolidated Operational Details

  Q1 Total   Q2 Total   Q3 Total   Q4 Total   2017 Total  
Production (Contained in Concentrates)*                    
Copper (000s pounds) 5,046   5,154   5,099   5,326   20,625  
Gold (ounces) 2,550   2,570   2,831   2,972   10,923  
Silver (ounces) 9,852   10,005   10,840   9,586   40,283  
Mine                    
Tonnes of ore mined 63,468   65,942   74,919   64,705   269,034  
Mill                    
Tonnes processed 62,885   62,802   66,443   63,948   256,078  
Tonnes processed per day 810   794   794   763   790  
Copper grade (%) 3.89   3.94   3.68   3.98   3.87  
Gold grade (g/t) 19.2   2.07   2.16   2.25   2.10  
Silver grade (g/t) 9.12   9.96   10.31   8.24   9.42  
Recoveries                    
Copper (%) 93.5   94.4   94.3   95.0   94.3  
Gold (%) 65.8   61.8   61.1   64.2   63.2  
Silver (%) 53.9   49.9   49.5   56.7   52.5  
Concentrates                    
Copper Concentrates (dmt) 10,566   10,460   10,551   11,224   42,801  
Copper (%) 21.7   22.3   21.9   21.5   21.8  
Gold (g/t) 7.5   7.6   8.4   8.2   7.9  
Silver (g/t) 29.0   29.7   32.0   26.5   29.3  
                     
Payable copper produced (000s lbs) 4,790   4,897   4,844   5,060   19,591  
Cash cost per pound of payable copper(1)(2) ($/lbs) 1.41   1.30   1.37   1.67   1.44  
* Subject to adjustments due to final settlement
 

(1) Alternative performance measures; please refer to "Non-GAAP Financial Measures" at the end of this release.
(2) Net of by-product credits
(3) Subject to adjustments on final settlement

The financial statements and MD&A are available on SEDAR and have also been posted on the company's website at http://aticomining.com/investors/financial-reports/

Annual General Meeting

Atico Mining cordially invites all shareholders to its Annual General and Special Meeting of Shareholders, at 10:00 am, Wednesday, May 30, 2018, at Suite 501 - 543 Granville Street Vancouver, British Columbia.

El Roble Mine

The El Roble mine is a high grade, underground copper and gold mine with nominal processing plant capacity of 800 tonnes per day, located in the Department of Choco in Colombia. Its commercial product is a copper-gold concentrate.

Since obtaining control of the mine on November 22, 2013, Atico has upgraded the operation from a historical nominal capacity of 400 tonnes per day.

El Roble has a measured and indicated resource of 1.87 million tonnes grading 3.46% copper and 2.27 g/t gold, at a cut-off grade of 0.93% copper equivalent. Mineralization is open at depth and along strike and the Company plans to further test the limits of the resource.

On the larger land package, the Company has identified a prospective stratigraphic contact between volcanic rocks and black and grey pelagic sediments and cherts that has been traced by Atico geologists for ten kilometers. This contact has been determined to be an important control on VMS mineralization on which Atico has identified numerous target areas prospective for VMS type mineralization occurrence, which is the focus of the current surface drill program at El Roble.

Qualified Person

Mr. Thomas Kelly (SME Registered Member 1696580), advisor to the Company and a qualified person under National Instrument 43-101 standards, is responsible for ensuring that the technical information contained in this news release is an accurate summary of the original reports and data provided to or developed by Atico.

About Atico Mining Corporation

Atico is a growth-oriented Company, focused on exploring, developing and mining copper and gold projects in Latin America. The Company operates the El Roble mine and is pursuing additional acquisition opportunities. For more information, please visit www.aticomining.com.

 

ON BEHALF OF THE BOARD

Fernando E. Ganoza
CEO
Atico Mining Corporation

Trading symbols: TSX.V: ATY | OTC: ATCMF

Investor Relations
Igor Dutina
Tel: +1.604.633.9022

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ''U.S. Securities Act''), or any state securities laws, and may not be offered or sold in the United States, or to, or for the account or benefit of, a "U.S. person" (as defined in Regulation S of the U.S. Securities Act) unless pursuant to an exemption therefrom. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction.

Cautionary Note Regarding Forward Looking Statements

This announcement includes certain "forward-looking statements" within the meaning of Canadian securities legislation. All statements, other than statements of historical fact, included herein, without limitation the use of net proceeds, are forward-looking statements. Forward-looking statements involve various risks and uncertainties and are based on certain factors and assumptions. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; uncertainty of estimates of capital and operating costs; the need to obtain additional financing to maintain its interest in and/or explore and develop the Company's mineral projects; uncertainty of meeting anticipated program milestones for the Company's mineral projects; and other risks and uncertainties disclosed under the heading "Risk Factors" in the prospectus of the Company dated March 2, 2012 filed with the Canadian securities regulatory authorities on the SEDAR website at  www.sedar.com

The Company has not based its production decisions and ongoing mine production on mineral reserve estimates, preliminary economic assessments or feasibility studies, and historically such projects have increased uncertainty and risk of failure. Mineral resources that are not mineral reserves do not have demonstrated economic viability.

Non-GAAP Financial Measures

The items marked with a "(1)" are alternative performance measures and readers should refer to Non-GAAP Financial Measures in the Company's Management's Discussion and Analysis for the year ended December 31, 2017 as filed on SEDAR and as available on the Company's website for further details.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Atico Mining Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum